Conquest - Spring 2014
MD Anderson establishes immunotherapy partnerships
by Scott Merville
MD Anderson will collaborate with Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech, Inc., MedImmune, Pfizer and GlaxoSmithKline to develop immunology-based cancer treatments through the MD Anderson Moon Shots Program’s immunotherapy platform.
The three-year translational research agreements bring together the scientific and clinical capabilities of MD Anderson and the global leaders in pharmaceutical and biotechnology development to strengthen the institution’s efforts to advance therapies that train the body’s immune system to combat cancer.
“Our new collaborations are different from traditional agreements because they allow both parties to work on any project they deem appropriate without additional budgets,” said Ferran Prat, Ph.D., J.D., vice president of strategic industry ventures.
“We provide our pharma and biotech collaborators access to state-of-the-art facilities, novel research protocols for clinical trials open to our large and diverse patient population, and an opportunity to work with leaders in the field of immunotherapy,” Prat added.
MD Anderson recognized the potential of immune-based therapies by creating one of the platforms that supports its Moon Shots Program, the institution’s 10-year commitment to more rapidly develop therapies and other interventions to significantly reduce deaths caused by the disease. The ultimate goal is for all cancers to become moon shots. The moons shots are supported by several platforms — infrastructure, technology or expertise — that support research efforts.
“We welcome the opportunity to work closely with these companies to build upon the early successes of immunotherapy by extending this approach to many types of cancer and exploring ways to improve treatment effectiveness,” said James Allison, Ph.D., chair of Immunology and executive director of the immunotherapy platform.
In This Issue
- Saying thanks to a champion of the struggle
- The pain won’t stop, but it won’t stop her
- The drug that may make chemo a thing of the past
- Understanding over-imaging
- Convenience comes standard at Rotary House
- Casting a wide network
- A tale of two proteins
- Invasive bladder and breast cancers bear a molecular resemblance
- Sensor-based technology benefits both patients and clinicians
- The write stuff improves outcomes
- Drugs team up to hit tumors, boost immune system attacks
- Blood test may one day reveal cancer
- MD Anderson immunotherapy pioneer’s List of awards keeps growing
- Screening tool targets body-image concerns
- MD Anderson establishes immunotherapy partnerships
- Leukemia chair picks up lifetime achievement honor